ClinicalTrials.gg

Hyperparathyroidism, Secondary clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 188 studies for Hyperparathyroidism, Secondary across more than 10 countries. 15 are recruiting or about to start. 122 of them are mainly about Hyperparathyroidism, Secondary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its narrower condition Chronic Kidney Disease-Mineral and Bone Disorder too: 247 studies, 34 open.

Status

Completed
139
Terminated
16
Status unknown
12
Recruiting
10
Not yet recruiting
5
Withdrawn
4

Phase

Phase 3
45
Phase 4
43
Phase 2
31
Phase 1
17

Where

United States
66
China
23
Germany
16
Spain
15
Italy
15
Japan
15

Who develops what

Add Hyperparathyroidism, Secondary to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 6 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine and OPKO Health here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CinacalcetRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07122401 · Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3 · live · comparator · “Cinacalcet” · registered Aug 2025
  • NCT05663411 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · comparator · “Cinacalcet” · registered Dec 2022
  • NCT03822507 · Kyowa Kirin Co., Ltd. · Phase 3 · comparator · “Cinacalcet Hydrochloride” · registered Jan 2019
  • NCT02549391 · Kyowa Kirin Co., Ltd. · Phase 3 · comparator · “KRN1493” · registered Sep 2015
  • NCT02216656 · Kyowa Kirin Co., Ltd. · Phase 2 · comparator · “KRN1493” · registered Aug 2014
Amgen91% of its industry studies22 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
MT1013☆ Track1 live phase-3 study: NCT07122401Shaanxi Micot Pharmaceutical Technology Co., Ltd.
upacicalcet sodium hydrate☆ Track1 live phase-3 study: NCT07890584Pathalys Pharma

The 2 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 26 Nov 2026 est.MT1013 · Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3 main aim+ MT1013 vs CinacalcetNCT07122401 Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism — primary endpoint: Percentage of participants with > 50% reduction from baseline in mean intact parathyroid (iPTH) · 424 enrolled
  • Oct 2027 est.Modified-release Calcifediol Capsule · OPKO Health, Inc. · Phase 2 main aimNCT07494045 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants — primary endpoint: Apparent clearance (CL/F) · 40 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hyperparathyroidism, Secondary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

5studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5, phase 3 first

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger. 4 (40%) take children under 18. 1 (10%) are for women only and 0 (0%) for men only; 1 (10%) take healthy volunteers.

Recruiting studies that take each age, of 10
AgeWomenMen
104 (40%)4 (40%)
187 (70%)6 (60%)
307 (70%)6 (60%)
407 (70%)6 (60%)
507 (70%)6 (60%)
657 (70%)6 (60%)
756 (60%)5 (50%)
855 (50%)5 (50%)

Across all 188 studies, recruiting or not: 21% stop at 75 or younger and 13% at 65; 14% take children; 2% are for women only and 1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperparathyroidism, Secondary studies take

Of 21 phase 3 interventional studies under Hyperparathyroidism, Secondary, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 322 mo14–31 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 188. Browse all 188 → or search them.